Ocugen (OCGN) has announced that the FDA has lifted the clinical hold on its investigational new drug application, allowing the initiation of a Phase 1 clinical trial for OCU200. This recombinant fusion protein, combining tumstatin and transferrin, targets the treatment of diabetic macular edema. The company is also exploring additional applications of OCU200 for potential use in treating diabetic retinopathy and wet age-related macular degeneration.
"We are thrilled to begin the Phase 1 clinical trial for OCU200, aimed at treating patients with DME," expressed Arun Upadhyay, Chief Scientific Officer and Head of Research & Development at Ocugen.
